{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Leukemia+of+Ambiguous+Lineage+in+Relapse", "query": { "condition": "Acute Leukemia of Ambiguous Lineage in Relapse" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 44, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Leukemia+of+Ambiguous+Lineage+in+Relapse&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T01:45:25.656Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02044796", "title": "Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "de Novo Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2014-01-23", "completion_date": "2018-04-16", "has_results": true, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02044796" }, { "nct_id": "NCT01319864", "title": "POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory AML", "Relapsed/Refractory ALL", "Secondary AML/MDS", "Acute Leukemia of Ambiguous Lineage", "AML", "ALL" ], "interventions": [ { "name": "Plerixafor Dose Escalation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "3 Years to 29 Years" }, "enrollment_count": 20, "start_date": "2011-03", "completion_date": "2016-06-28", "has_results": false, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Denver, Colorado • Atlanta, Georgia + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319864" }, { "nct_id": "NCT02141828", "title": "A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Acute Leukemias" ], "interventions": [ { "name": "EPZ-5676", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Months to 18 Years" }, "enrollment_count": 18, "start_date": "2014-05", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02141828" }, { "nct_id": "NCT03843528", "title": "Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Mixed Phenotype Acute Leukemia", "Juvenile Myelomonocytic Leukemia" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Azacitidine Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins All Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 15, "start_date": "2019-05-01", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 1, "location_summary": "St. Petersburg, Florida", "locations": [ { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03843528" }, { "nct_id": "NCT06533579", "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia", "Large B-cell Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Burkitt Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Non Hodgkin Lymphoma", "Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Dose Level 1, VNX-101", "type": "GENETIC" }, { "name": "Dose Level 2, VNX-101", "type": "GENETIC" }, { "name": "Dose Level 3, VNX-101", "type": "GENETIC" }, { "name": "Dose Level 4, VNX-101", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Vironexis Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "13 Years to 90 Years" }, "enrollment_count": 32, "start_date": "2025-05-30", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Valhalla", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533579" }, { "nct_id": "NCT04501614", "title": "A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)", "Ph+ Mixed Phenotype Acute Leukemia (MPAL)", "Philadelphia Chromosome-Like ALL (Ph-like ALL)" ], "interventions": [ { "name": "Ponatinib", "type": "DRUG" }, { "name": "Chemotherapy Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 11, "start_date": "2021-02-24", "completion_date": "2024-07-19", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501614" }, { "nct_id": "NCT01132573", "title": "Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 27, "start_date": "2010-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-07-17", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 4, "location_summary": "Aurora, Colorado • Denver, Colorado • Baltimore, Maryland", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132573" }, { "nct_id": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes, de Novo", "Myelodysplastic Syndromes, Secondary", "Myelodysplastic Syndromes, Previously Treated", "Treatment-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia With Failed Remission", "Lymphoblastic Lymphoma, in Relapse", "Lymphoblastic Lymphoma, Refractory", "Acute Leukemia of Ambiguous Lineage in Relapse", "Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew E. Place, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "40 Years", "sex": "ALL", "summary": "1 Year to 40 Years" }, "enrollment_count": 30, "start_date": "2023-03-29", "completion_date": "2030-07-02", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 5, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292664" }, { "nct_id": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Small Intestine Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "liposomal vincristine sulfate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 22, "start_date": "2009-06", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00933985" }, { "nct_id": "NCT04065399", "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Mixed Lineage Acute Leukemia", "Mixed Phenotype Acute Leukemia", "Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "revumenib", "type": "DRUG" }, { "name": "cobicistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": null, "sex": "ALL", "summary": "30 Days and older" }, "enrollment_count": 447, "start_date": "2019-11-05", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-06-26T01:45:25.656Z", "location_count": 22, "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 17 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04065399" } ] }